KRAS and neoplasm: ✓Additive tumor growth delay of KRAS-driven (including TP53-null) PDX NSCLC and ↑ apoptosis✓Similar therapeutic efficacy to cisplatin/paclitaxel, but displayed coagulative necrosis, ↓ p-AKT and p-p38